Publicaciones en colaboración con investigadores/as de University of Eastern Piedmont Amadeo Avogadro (19)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  3. Global disparities in surgeons’ workloads, academic engagement and rest periods: the on-calL shIft fOr geNEral SurgeonS (LIONESS) study

    Updates in Surgery, Vol. 76, Núm. 5, pp. 1615-1633

  4. Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

    HemaSphere

2023

  1. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)

    Leukemia

  2. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Leukemia, Vol. 37, Núm. 2, pp. 339-347

  3. Investigating the Prognostic Role of Peripheral Inflammatory Markers in Mild Cognitive Impairment

    Journal of Clinical Medicine, Vol. 12, Núm. 13

  4. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

    eClinicalMedicine, Vol. 65

2022

  1. Recovery of dialysis patients with COVID-19: health outcomes 3 months after diagnosis in ERACODA

    Nephrology Dialysis Transplantation, Vol. 37, Núm. 6, pp. 1140-1151

  2. Sex differences in COVID-19 mortality risk in patients on kidney function replacement therapy

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. Clinical triage of patients on kidney replacement therapy presenting with COVID-19: An ERACODA registry analysis

    Nephrology Dialysis Transplantation, Vol. 36, Núm. 12, pp. 2308-2320

  2. Crystallization, luminescence and cytocompatibility of hexagonal calcium doped terbium phosphate hydrate nanoparticles

    Nanomaterials, Vol. 11, Núm. 2, pp. 1-19

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. COVID-19-related mortality in kidney transplant and dialysis patients: Results of the ERACODA collaboration

    Nephrology Dialysis Transplantation, Vol. 35, Núm. 11, pp. 1973-1983

2018

  1. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

2017

  1. FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study

    Leukemia and Lymphoma, Vol. 58, Núm. 2, pp. 372-381

  2. Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents

    Journal of Clinical Oncology, Vol. 35, Núm. 14, pp. 1591-1597

2015

  1. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction

    Leukemia Research, Vol. 39, Núm. 3, pp. 296-306

  2. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell non-hodgkin lymphoma: Final analysis of the GAUSS study

    Journal of Clinical Oncology